Discover how orforglipron, a first‑in‑class oral GLP‑1 receptor agonist, delivers injectable‑level weight loss and glycemic control in a once‑daily pill, with phase 2 data in obesity and type 2 diabetes.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs